We are live on ! Find out more
ACIU icon

AC Immune
ACIU

39 hedge funds and large institutions have $191M invested in AC Immune in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 8

25% more capital invested

Capital invested by funds: $153M → $191M (+$38.2M)

22% more funds holding

Funds holding: 32 → 39 (+7)

1.65% more ownership

Funds ownership: 28.41% → 30.06% (+1.6%)

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

Holders
39
Holders Change
+7
Holders Change %
+21.88%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
7
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$6.82M
2
BlackRock
BlackRock
New York
+$6.09M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.81M
4
BI
BVF Inc
California
+$2.01M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.56M

Top Sellers

Rank Fund Capital Flow
1
PC
PointState Capital
New York
-$4.51M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$4.13M
3
SFM
Sphera Funds Management
Israel
-$1.82M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$844K
5
BAM
Belpointe Asset Management
Nevada
-$400K
Name Holding Trade Value Shares
Change 		Change in
Stake
OAM
26
Oxford Asset Management
United Kingdom
$216K +$216K +22,847 New
ProShare Advisors
27
ProShare Advisors
Maryland
$184K +$184K +19,442 New
PCM
28
Prelude Capital Management
New York
$184K +$184K +19,515 New
ARTA
29
A.R.T. Advisors
New York
$180K +$180K +19,032 New
TD Asset Management
30
TD Asset Management
Ontario, Canada
$165K – – –
LBC
31
Lawrence B. Cohen
$126K -$14.2K -1,500 -10%
Squarepoint
32
Squarepoint
New York
$121K +$121K +12,800 New
QSS
33
Quantitative Systematic Strategies
Florida
$102K +$102K +10,757 New
Barclays
34
Barclays
United Kingdom
$61K +$52.9K +5,606 +726%
Bank of America
35
Bank of America
North Carolina
$30K +$29.6K +3,140 New
MWNA
36
Marshall Wace North America
New York
$21K +$20.6K +2,182 New
UBS Group
37
UBS Group
Switzerland
$8K -$16K -1,694 -67%
Daiwa Securities Group
38
Daiwa Securities Group
Japan
$6K +$5.67K +600 New
PC
39
PointState Capital
New York
– -$4.51M -563,850 Closed
BAM
40
Belpointe Asset Management
Nevada
– -$400K -50,000 Closed
Arrowstreet Capital
41
Arrowstreet Capital
Massachusetts
– -$173K -21,644 Closed
Deutsche Bank
42
Deutsche Bank
Germany
– -$168K -21,000 Closed
JP Morgan Chase
43
JP Morgan Chase
New York
– -$142K -17,803 Closed
GCP
44
GSA Capital Partners
United Kingdom
– -$110K -13,801 Closed
TRCT
45
Tower Research Capital (TRC)
New York
– -$32K -4,018 Closed
EDRH
46
Edmond de Rothschild Holding
Switzerland
– -$10K -1,241 Closed
S
47
SignatureFD
Georgia
– +$38 +4 New
1
2

ACIU Hedge Fund Activity: Q4 2018 in Review

39 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q4 2018, worth a combined $191M — up 25% from $153M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ACIU positions and 8 closed out — a net gain of 7 holders — while 7 added to existing stakes and 10 trimmed.

The largest buyer was Marshall Wace, adding an estimated $6.82M. The largest seller was PointState Capital, exiting entirely with an estimated $4.51M sold.

  • 39 institutional investors held AC Immune (ACIU) as of Q4 2018, up from 32 in Q3 2018.
  • Funds reported $191M of AC Immune stock for Q4 2018, up 25% quarter-over-quarter.
  • 15 funds opened new AC Immune positions in Q4 2018 and 8 closed out, a net change of +7 holders.
  • The largest AC Immune buyer in Q4 2018 was Marshall Wace, an estimated $6.82M added.
  • The largest AC Immune seller in Q4 2018 was PointState Capital, an estimated $4.51M sold.

Based on aggregated 13F filings for Q4 2018.